Successful treatment of a patient with refractory immune thrombocytopenic purpura in systemic lupus erythematosus with rituximab.
Immunol Med
; 42(4): 185-188, 2019 Dec.
Article
en En
| MEDLINE
| ID: mdl-31794352
ABSTRACT
Immune thrombocytopenic purpura (ITP) is one of the complications of systemic lupus erythematosus (SLE). Although corticosteroids are usually selected for initial therapy, some patients are corticosteroid-resistant and, therefore, require other immunosuppressants or splenectomy. However, the best treatment approach in such patients remains unknown, and there is little evidence regarding which immunosuppressive agent can provide best results. We report the case of a patient with corticosteroid-resistant SLE-associated ITP (SLE-ITP) who was successfully treated with rituximab (RTX). RTX might be a therapeutic option for corticosteroid-resistant SLE-ITP.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Púrpura Trombocitopénica Idiopática
/
Rituximab
/
Lupus Eritematoso Sistémico
Tipo de estudio:
Etiology_studies
Límite:
Aged
/
Female
/
Humans
Idioma:
En
Revista:
Immunol Med
Año:
2019
Tipo del documento:
Article
País de afiliación:
Japón